São Paulo Confirms Mounjaro Use for Two Players and Rejects Link to Injury Surge

Overview

• São Paulo said on Friday that two professionals received Mounjaro after specific clinical evaluations, characterizing the use as individual and not generalized.
• The club called any causal link to the team’s injury totals dishonest and noted the drug is an Eli Lilly product approved in Brazil for diabetes and, in some cases, weight control.
• Injury context reported this season includes 24 of 33 players with injuries or medical-department stints as of November, with other accounts citing roughly 70 injury occurrences.
• Reports name club nutrólogo Dr. Eduardo Rauen as the prescriber for the two cases, and São Paulo stated his conduct met medical criteria and remains supported by the organization.
• Coverage describes internal disagreements in the health area and notes announced staffing changes and process restructuring for 2026, with no regulatory sanctions reported.